2022-500930-27-00已完成1 期
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
Celgene Corp., Celgene Corp.11 个研究点 分布在 3 个国家目标入组 48 人开始时间: 2023年7月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 11
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (11)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma2023-506003-26-00Celgene Corp.19
未知
1 期
Phase 1 Study of BMS-986148jRCT2080223357Bristol-Myers Squibb K.K.15
进行中（未招募）
1 期
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced CancersAdvanced Malignant TumorsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2015-004914-79-PLBristol-Myers Squibb International Corporation907
进行中（未招募）
1 期
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced CancersAdvanced Malignant TumorsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2015-004914-79-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO627
进行中（未招募）
1 期
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced CancersAdvanced Malignant TumorsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2015-004914-79-NOBristol-Myers Squibb International Corporation627